Literature DB >> 17502042

The role of preventive cardiology in systemic lupus erythematosus.

Jennifer Rae Elliott1, Susan Manzi, Daniel Edmundowicz.   

Abstract

With improved therapeutic advances in the care of systemic lupus erythematosus patients, cardiovascular disease has emerged as a leading cause of death. Premature atherosclerosis in lupus patients is probably an interaction between traditional cardiovascular risk factors, inflammatory factors, and factors related to lupus itself. Despite knowledge of this accelerated cardiac risk, evaluation of traditional risk factors has been sub-par. We propose that lupus patients be evaluated by preventive cardiologists and have access to their expertise and resources. In addition to nephrologists and dermatologists, preventive cardiologists should be an integral part of the care of patients with lupus.

Entities:  

Mesh:

Year:  2007        PMID: 17502042     DOI: 10.1007/s11926-007-0006-1

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  54 in total

1.  Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies.

Authors:  E F Borba; E Bonfá
Journal:  Lupus       Date:  1997       Impact factor: 2.911

2.  High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk.

Authors:  E V Barnes; S Narain; A Naranjo; J Shuster; M S Segal; E S Sobel; A E Armstrong; B E Santiago; W H Reeves; H B Richards
Journal:  Lupus       Date:  2005       Impact factor: 2.911

3.  Vascular events in hypertensive patients with systemic lupus erythematosus.

Authors:  P Rahman; S Aguero; D D Gladman; D Hallett; M B Urowitz
Journal:  Lupus       Date:  2000       Impact factor: 2.911

4.  Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages.

Authors:  Y Hasunuma; E Matsuura; Z Makita; T Katahira; S Nishi; T Koike
Journal:  Clin Exp Immunol       Date:  1997-03       Impact factor: 4.330

5.  Premature coronary-artery atherosclerosis in systemic lupus erythematosus.

Authors:  Yu Asanuma; Annette Oeser; Ayumi K Shintani; Elizabeth Turner; Nancy Olsen; Sergio Fazio; MacRae F Linton; Paolo Raggi; C Michael Stein
Journal:  N Engl J Med       Date:  2003-12-18       Impact factor: 91.245

6.  Risk factors for cardiovascular disease in systemic lupus erythematosus.

Authors:  E Svenungsson; K Jensen-Urstad; M Heimbürger; A Silveira; A Hamsten; U de Faire; J L Witztum; J Frostegård
Journal:  Circulation       Date:  2001-10-16       Impact factor: 29.690

7.  Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus.

Authors:  Faith Selzer; Kim Sutton-Tyrrell; Shirley G Fitzgerald; Joan E Pratt; Russell P Tracy; Lewis H Kuller; Susan Manzi
Journal:  Arthritis Rheum       Date:  2004-01

8.  Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis.

Authors:  M Petri; C Lakatta; L Magder; D Goldman
Journal:  Am J Med       Date:  1994-03       Impact factor: 4.965

9.  Risk factors for coronary artery disease in patients with systemic lupus erythematosus.

Authors:  M Petri; S Perez-Gutthann; D Spence; M C Hochberg
Journal:  Am J Med       Date:  1992-11       Impact factor: 4.965

10.  Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus.

Authors:  Elisabet Svenungsson; Iva Gunnarsson; Guo-Zhong Fei; Ingrid E Lundberg; Lars Klareskog; Johan Frostegård
Journal:  Arthritis Rheum       Date:  2003-09
View more
  7 in total

1.  Short-term patient-centered nutrition counseling impacts weight and nutrient intake in patients with systemic lupus erythematosus.

Authors:  S T Everett; R Wolf; I Contento; V Haiduc; M Richey; D Erkan
Journal:  Lupus       Date:  2015-04-29       Impact factor: 2.911

Review 2.  Accelerated vascular disease in systemic lupus erythematosus: role of macrophage.

Authors:  Mohammed M Al Gadban; Mohamed M Alwan; Kent J Smith; Samar M Hammad
Journal:  Clin Immunol       Date:  2015-01-28       Impact factor: 3.969

3.  Anti-apolipoprotein A-1 antibodies and carotid intima-media thickness in Egyptian women with systemic lupus erythematosus.

Authors:  M M Radwan; D El-Lebedy; R Fouda; E Elsorougy
Journal:  Clin Rheumatol       Date:  2014-04       Impact factor: 2.980

4.  Lack of nitric oxide synthases increases lipoprotein immune complex deposition in the aorta and elevates plasma sphingolipid levels in lupus.

Authors:  Mohammed M Al Gadban; Jashalynn German; Jean-Philip Truman; Farzan Soodavar; Ellen C Riemer; Waleed O Twal; Kent J Smith; Demarcus Heller; Ann F Hofbauer; Jim C Oates; Samar M Hammad
Journal:  Cell Immunol       Date:  2012-04-04       Impact factor: 4.868

5.  IgG anti-apolipoprotein A-1 antibodies in patients with systemic lupus erythematosus are associated with disease activity and corticosteroid therapy: an observational study.

Authors:  Sara Croca; Paul Bassett; Sharon Chambers; Maria Davari; Karim Fouad Alber; Oliver Leach; Yiannis Ioannou; Ian Giles; David Isenberg; Anisur Rahman
Journal:  Arthritis Res Ther       Date:  2015-02-09       Impact factor: 5.156

6.  Cardiovascular disease in latin american patients with systemic lupus erythematosus: a cross-sectional study and a systematic review.

Authors:  Jenny Amaya-Amaya; Juan Camilo Sarmiento-Monroy; Julián Caro-Moreno; Nicolás Molano-González; Rubén D Mantilla; Adriana Rojas-Villarraga; Juan-Manuel Anaya
Journal:  Autoimmune Dis       Date:  2013-11-03

Review 7.  Cardiovascular involvement in autoimmune diseases.

Authors:  Jenny Amaya-Amaya; Laura Montoya-Sánchez; Adriana Rojas-Villarraga
Journal:  Biomed Res Int       Date:  2014-07-22       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.